Ultralife Corp (NASDAQ:ULBI) President and Chief Executive Officer Michael Edward Manna reported insider purchases of the company’s common stock on March 12, 2026. According to the filing, Manna acquired a total of 2,000 shares in two separate transactions, with prices ranging from $6.01 to $6.031, for an aggregate cost of $12,024.
The insider buying arrived as the stock had climbed roughly 23% over the previous week, with shares trading at $7.03 at the time of reporting. Following the March 12 transactions, Manna directly holds 26,874 shares of Ultralife.
Market commentary included with the filing noted that InvestingPro’s analysis identifies the stock as appearing undervalued at current levels and lists the company on its Most Undervalued roster. The platform also references a detailed Pro Research Report available exclusively through InvestingPro for investors seeking deeper valuation and company analysis.
Recent earnings snapshot
Ultralife reported fourth-quarter 2025 results that combined an earnings beat with a revenue shortfall. The company posted earnings per share of $0.45, topping the consensus estimate of $0.24 - an 87.5% surprise versus expectations. Revenue for the quarter totaled $48.5 million, below the anticipated $57.0 million and representing a negative surprise of 14.91%.
The results have prompted attention to the company’s strategic initiatives, though there were no new analyst upgrades or downgrades reported during this period.
Key points
- CEO Michael Edward Manna purchased 2,000 shares on March 12, 2026, spending $12,024 across two trades at $6.01 to $6.031.
- Ultralife’s stock rose about 23% over the prior week and was trading at $7.03 when the insider purchases were reported.
- Fourth-quarter 2025 results showed an EPS beat ($0.45 versus $0.24 forecast) and a revenue miss ($48.5 million versus $57.0 million expected). InvestingPro lists the stock among Most Undervalued names and offers a Pro Research Report for subscribers.
Sectors impacted - The developments are most relevant to equity investors following small-cap manufacturing and specialty technology stocks, and to market participants focused on insider activity and corporate valuation assessments.
Risks and uncertainties
- The company reported a revenue shortfall for Q4 2025, introducing uncertainty around near-term top-line performance that may affect investor sentiment in the equity market.
- Analyst coverage showed no new upgrades or downgrades in the period referenced, leaving valuation and rating signals unchanged and potentially limiting near-term clarity for investors.
- The InvestingPro designation of the stock as appearing undervalued reflects an analytical view but does not remove execution or market risks tied to future results and trading volatility.
Investors looking for full valuation detail can consult the Pro Research Report referenced by InvestingPro for expanded analysis.